Lakefront Biotherapeutics revenue and financials
€25.90Change from previous close: −1.97%Absolute change: −€0.52
In the fiscal year ended December 2025, Lakefront Biotherapeutics reported revenue of €1.11B (+303.50% year over year). Net income was €320.88M, a net margin of 28.9%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +303.50%
- 2025 vs 2024
- Net income growth
- +333.15%
- 2025 vs 2024
- Net margin
- 28.9%
- 2024: 26.9%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Total assets | 3,351 | 3,372 | 3,407 | 3,512 | 3,818 | — |
| Current assets | 2,309 | 3,061 | 3,079 | 3,162 | 3,255 | — |
| Cash and equivalents | 136 | 66.8 | 87.9 | 64.5 | 71.7 | — |
| Short-term investments | 2,104 | 2,915 | 2,910 | 2,986 | 3,020 | — |
| Receivables | 56.3 | 54.0 | 53.2 | 77.7 | 87.8 | — |
| Inventory | 8.5 | 17.7 | 22.5 | 22.9 | 33.8 | — |
| Net property, plant and equipment | 76.9 | 77.0 | 80.7 | 106 | 110 | — |
| Goodwill | — | — | 0.0 | 0.0 | 69.2 | 69.7 |
| Other intangible assets | 751 | 0.7 | 0.8 | 7.4 | 147 | — |
| Long-term investments | 73.9 | 47.9 | 46.8 | 46.8 | 46.9 | — |
| Current liabilities | 70.3 | 100 | 153 | 367 | 403 | — |
| Accounts payable | 66.3 | 95.8 | 32.6 | 101 | 133 | — |
| Total debt | 6.4 | 6.4 | 6.9 | 7.5 | 8.4 | — |
| Total liabilities | 87.6 | 119 | 171 | 1,065 | 1,174 | — |
| Total equity (incl. minority) | 3,264 | 3,253 | 3,236 | 2,447 | 2,644 | — |
| Retained earnings | 234 | 228 | 211 | -578 | -381 | — |